A Phase 2 interventional study of BMS-TACE and Lenvatinib in Hepatocellular Carcinoma, Portal Vein Tumor Thrombus and Hepatic Vein Tumor Thrombus, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University — 58 open to participants now, 65 under way, 10 of them phase 3. Carcinoma, Hepatocellular · Sun Yat-sen University.
Among the 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University, this one is the 121st largest by planned enrollment of the 161 interventional ones that give a count, is one of 6 that started in 2026, is one of 55 in phase 2, reaches primary completion later than 59 of the 64 other live ones, and was the 186th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,067 are open to participants now.
Browse Carcinoma, Hepatocellular studies →58 of the 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 742 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 252 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 61 · Phase 3 54 · Phase 4 18
First in 2002; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is below the median of 53 across 2,622 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 120 across the 161 interventional studies, 200 across the 26 observational. Of the 41 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.
13 of the studies in Carcinoma, Hepatocellular by Sun Yat-sen University that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368651Phase 3Sun Yat-sen UniversityThe Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | 2026-11-30 |
| NCT05718232Phase 3Sun Yat-sen UniversitySBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) | 2027-02 |
| NCT06041477Phase 3Sun Yat-sen UniversityConcurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | 2027-07 |
| NCT02785380Sun Yat-sen UniversityLaparoscopic Surgery VS RFA for Recurrent HCC | 2026-12 |
| NCT07192185Sun Yat-sen UniversitySystemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | 2026-12-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 187 studies in Carcinoma, Hepatocellular by Sun Yat-sen University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hepatocellular carcinoma (HCC) with macrovascular tumor thrombus carries a poor prognosis, and systemic therapy alone provides limited benefit in this population. This single-center, single-arm, phase 2 trial evaluates the efficacy and safety of a regimen combining chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE), low-dose lenvatinib, the anti-PD-1/CTLA-4 bispecific antibody iparomlimab and tuvonralimab, and stereotactic body radiotherapy (SBRT). In BMS-TACE, blank microspheres are the principal embolic agent and chemotherapy is used only as an adjunct at a fixed, minimal dose (doxorubicin 10 mg and lobaplatin 10 mg), in order to limit chemotherapy-related liver injury and systemic toxicity and to allow repeated embolization in patients with limited hepatic reserve. Forty-two participants with BCLC stage C HCC and tumor thrombus in the main portal vein or superior mesenteric vein (Vp3/Vp4), hepatic vein, or inferior vena cava, without extrahepatic metastases, will be enrolled. The primary endpoint is progression-free survival assessed by blinded independent central review using mRECIST.
Rationale. Patients with HCC and macrovascular invasion derive limited benefit from systemic therapy; in the Vp4 subgroup of IMbrave150, median overall survival with atezolizumab plus bevacizumab was 7.6 months. Locoregional therapy added to systemic therapy may improve tumor control, and radiotherapy is effective against tumor thrombus and is not limited by arterial blood supply. The investigators previously completed the TALEM trial (NCT05555316; Liver Cancer 2024;13:438-450), a prospective single-arm phase 2 study of BMS-TACE with low-dose chemotherapy plus low-dose lenvatinib and microwave ablation in large unresectable HCC, which reported a downstaging rate of 86.0%, an objective response rate of 93.0% by mRECIST, median progression-free survival of 14.7 months, and median overall survival of 36.4 months. In that study, myeloid-derived suppressor cells declined significantly and CXCR5-expressing CD4+ and CD8+ T cells increased significantly 24 hours after the first BMS-TACE, and participants with a decline in monocytic myeloid-derived suppressor cells had significantly better overall survival. These findings provide the mechanistic basis for adding an immune checkpoint inhibitor to BMS-TACE in the present trial.
Treatment. One cycle is defined as 21 days, matching the dosing interval of iparomlimab and tuvonralimab. Cycle 1 Day 1 is the day of the first BMS-TACE. Lenvatinib and iparomlimab and tuvonralimab both begin 3 to 7 days after the first BMS-TACE. BMS-TACE is repeated according to protocol-defined retreatment criteria, generally with two complete sessions followed by additional sessions as needed. SBRT is delivered with a minimum interval of 14 days from any BMS-TACE in either direction, and targets the tumor thrombus first; once the thrombus is devitalized, SBRT may be used to consolidate residual viable intrahepatic lesions. If a high-flow arterioportal or arteriohepatic venous shunt is identified at the first BMS-TACE that precludes safe embolization, SBRT to the tumor thrombus is brought forward to week 3 after the first BMS-TACE, and BMS-TACE is resumed after the shunt has diminished.
Assessments. Tumor assessments are performed by three-phase dynamic contrast-enhanced CT or dynamic contrast-enhanced liver MRI, using the same modality and protocol throughout for a given participant. Imaging is read centrally by two blinded independent radiologists using both mRECIST and RECIST 1.1, with adjudication by a third radiologist in case of disagreement; investigator assessment is performed in parallel for clinical decision-making and sensitivity analyses. Because BMS-TACE and SBRT act mainly by inducing tumor necrosis rather than shrinkage, and because pseudoprogression may occur with immune checkpoint inhibition, participants with a first radiological finding of progression but clinically stable disease may continue treatment and undergo confirmatory imaging 4 to 8 weeks later; when progression is confirmed, the event date is the date of the first documented progression.
Safety oversight. An independent Data and Safety Monitoring Committee reviews accumulating safety data, with a first meeting after the first 10 participants have completed one cycle and protocol-defined rules for holding enrollment.
Exploratory objectives. Peripheral blood is collected at baseline (1 to 3 days before the first BMS-TACE), 24 hours, 1 month and 3 months after the first BMS-TACE, and at disease progression or end of treatment, and immune cell subsets are characterized by flow cytometry and single-cell RNA sequencing. Pretreatment tumor tissue, and post-treatment tumor tissue obtained at conversion surgery or by biopsy at documented objective response or disease progression, is analyzed by single-cell RNA sequencing and spatial transcriptomics to characterize changes in the tumor microenvironment. The relationship of these changes with response and survival is explored.
Design rationale: de-escalation. Several phase 3 trials that added systemic therapy to TACE have reported a consistent pattern in which progression-free survival was met but overall survival was not. In LEAP-012, median progression-free survival was 14.6 versus 10.0 months (hazard ratio 0.66) while the interim overall survival hazard ratio was 0.80 (95% CI 0.57-1.11; p=0.087). In EMERALD-1, median progression-free survival was 15.0 versus 8.2 months (hazard ratio 0.77; p=0.032). In EMERALD-3, median progression-free survival was 13.0 versus 9.8 months (hazard ratio 0.70; p=0.0007), whereas median overall survival was 39.5 versus 34.7 months (hazard ratio 0.84; 95% CI 0.65-1.09; p=0.18). In TALENTACE, median TACE progression-free survival was 11.3 versus 7.0 months (hazard ratio 0.71; p=0.0089) with an interim overall survival hazard ratio of 0.96. The cost is recorded in the safety data: grade 3 or higher treatment-related adverse events occurred in 71% of participants in LEAP-012 versus 32% with TACE alone, and serious adverse events in 64% versus 23% in EMERALD-3, in which adding lenvatinib produced no incremental progression-free survival benefit (hazard ratio 0.94) yet raised discontinuation for adverse events from 21% to 36%.
This trial is therefore designed around de-escalation rather than intensification, on three premises: that toxicity truncates the time a participant remains on effective therapy and thereby erodes the advantage gained during first-line disease control; that cirrhosis is a concurrent disease in hepatocellular carcinoma, so tumour shrinkage obtained at the cost of liver injury removes eligibility for the subsequent therapy from which much of overall survival derives; and that agents added to an already adequate backbone tend to act additively rather than synergistically. Four design features follow. Embolization rather than chemotherapy is the principal antitumour mechanism, with a fixed minimal chemotherapy dose that may be omitted in later sessions according to response. Lenvatinib is given at a low dose, which both improves long-term tolerability and avoids the vascular pruning that would compromise repeated super-selective catheterization. SBRT carries the local intensity required for the tumour thrombus without adding systemic toxicity. Treatment is deliberately separated in time, both to limit overlapping toxicity and to preserve the T-cell proliferative response that concurrent cytotoxic therapy would blunt. Treatment exposure intensity, including lenvatinib relative dose intensity, cycles completed, and discontinuation due to adverse events, is examined in a protocol-specified exploratory analysis of whether this strategy achieves its intended effect.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive chemotherapy-minimized, blank microsphere-based transarterial chemoembolization (BMS-TACE) on Cycle 1 Day 1. Low-dose lenvatinib and iparomlimab and tuvonralimab both start 3 to 7 days after the first BMS-TACE. Stereotactic body radiotherapy is delivered to the macrovascular tumor thrombus with a minimum interval of 14 days from any BMS-TACE in either direction. One cycle is 21 days.
Procedure: BMS-TACE · Drug: Lenvatinib · Drug: Iparomlimab and Tuvonralimab · Radiation: Stereotactic Body Radiotherapy
Visceral angiography of the celiac trunk, superior mesenteric artery and, as indicated, collateral arteries maps the arterial supply of the tumor and tumor thrombus and identifies arteriovenous shunting. A 2.8F microcatheter is placed super-selectively into tumor-feeding arteries by coaxial technique. A fixed, minimal-dose chemoemulsion (doxorubicin 10 mg and lobaplatin 10 mg in about 5 mL lipiodol) is injected slowly; chemotherapy may be omitted in later sessions according to tumor response, leaving blank-microsphere embolization alone. Blank microspheres are then delivered in ascending size order (40-120, 100-300, then 300-500 or 500-700 microns). The endpoint is contrast stasis over 3-5 cardiac cycles plus angiography 5-10 minutes later confirming loss of more than 90% of tumor staining. Imaging is repeated 4-6 weeks after each session; retreatment follows protocol-defined criteria. Participants generally receive two complete sessions.
Lenvatinib 8 mg orally once daily for body weight 60 kg or above, or 4 mg orally once daily for body weight below 60 kg, started 3 to 7 days after the first BMS-TACE. Lenvatinib is withheld on the day of each BMS-TACE or SBRT and resumed 3 to 5 days afterwards provided the Child-Pugh score is 5 to 8; cumulative interruption does not exceed 3 weeks. Treatment continues until disease progression, unacceptable toxicity, or withdrawal of consent.
Drug pages: IparomlimabStudies of IparomlimabIparomlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TuvonralimabStudies of TuvonralimabTuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Iparomlimab and tuvonralimab (QL1706), an anti-PD-1/anti-CTLA-4 bispecific antibody combination, 5 mg/kg intravenously every 3 weeks, infused over at least 30 minutes. Dosing starts 3 to 7 days after the first BMS-TACE and is separated from any BMS-TACE by at least 3 days. Treatment continues until disease progression or unacceptable toxicity. Immune-related adverse events are managed according to protocol-defined rules, including dose interruption, corticosteroid therapy and permanent discontinuation criteria.
Also known as: QL1706
Stereotactic body radiotherapy directed primarily at the macrovascular tumor thrombus. Simulation uses vacuum-bag or thermoplastic immobilization with 4D-CT or gated CT (slice thickness 3 mm or less). The prescription is 30 to 50 Gy in 5 to 10 fractions, individualized by tumor size and location, normal liver volume and Child-Pugh score: 40-50 Gy in 5 fractions when normal liver volume is 700 mL or more with Child-Pugh 5-6; 35-40 Gy in 5-8 fractions when normal liver volume is 500-700 mL or Child-Pugh is 7; and 30-40 Gy in 10 fractions when the target is within 1 cm of stomach, duodenum or colon. The prescription covers at least 95% of the planning target volume. Daily kV cone-beam CT image guidance is used with setup correction to within 3 mm. A minimum interval of 14 days separates SBRT and BMS-TACE in either direction.
Progression-free survival (PFS) by blinded independent central review (BICR) using mRECIST
Time from Cycle 1 Day 1 (the day of the first BMS-TACE) to the first objective disease progression confirmed by blinded independent central review using mRECIST, or death from any cause, whichever occurs first. Participants without an event are censored at the last evaluable tumor assessment; participants starting a new anticancer therapy not specified in the protocol without documented progression are censored at that date; events occurring after two or more consecutively missed scheduled assessments are censored at the last evaluable assessment. RECIST 1.1 and investigator assessment are applied as sensitivity analyses.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months (14-month accrual plus 12 months of follow-up after the last participant is enrolled)
Overall survival (OS)
Time from Cycle 1 Day 1 to death from any cause. Participants alive are censored at the date last known to be alive.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Progression-free survival 2 (PFS2)
Time from Cycle 1 Day 1 to the second objective disease progression documented during subsequent therapy, or death from any cause, whichever occurs first.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Objective response rate (ORR)
Proportion of participants with a best overall response of complete or partial response by blinded independent central review using mRECIST, confirmed by repeat imaging at least 4 weeks later.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Disease control rate (DCR)
Proportion of participants with a best overall response of complete response, partial response or stable disease by blinded independent central review using mRECIST.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Duration of response (DOR)
Time from the first documented complete or partial response to the first documented disease progression or death from any cause.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Time to untreatable progression (TTUP)
Time from Cycle 1 Day 1 to the date on which BMS-TACE is judged no longer feasible according to the protocol-defined criteria for technical infeasibility or BMS-TACE refractoriness.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Time to extrahepatic spread
Time from Cycle 1 Day 1 to the first radiological documentation of extrahepatic metastasis.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Time to new vascular invasion
Time from Cycle 1 Day 1 to the first radiological documentation of new macrovascular invasion.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Conversion rate to surgical resection
Proportion of all enrolled participants judged by a multidisciplinary team to have become eligible for surgical resection, defined as successful downstaging, adequate future liver remnant and technical resectability.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Conversion rate to surgical resection or ablation
Proportion of all enrolled participants judged eligible for surgical resection or ablation. Ablation eligibility is defined as 5 or fewer lesions, each 5 cm or smaller.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) up to approximately 26 months
Change from baseline in EORTC QLQ-C30 scores
Change from baseline in the functional scale, symptom scale and global health status/quality of life scores of the EORTC QLQ-C30 (version 3.0). Scores range from 0 to 100; for functional scales and global health status, higher scores indicate better functioning, whereas for symptom scales higher scores indicate worse symptoms.
Time frame: Baseline and Day 1 of each 21-day cycle from Cycle 2 until the end-of-treatment visit, up to approximately 26 months
Incidence and severity of adverse events and procedure-related complications
Incidence and severity of adverse events, serious adverse events, and BMS-TACE- and SBRT-related procedural complications, graded by CTCAE version 5.0. Major complications are defined as those requiring escalation of care, prolonged hospitalization, readmission, or resulting in permanent sequelae.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) to 30 days after the last dose of study treatment
Change from baseline in EORTC QLQ-HCC18 scores
Change from baseline in the symptom scale scores of the EORTC QLQ-HCC18 hepatocellular carcinoma-specific module. Scores range from 0 to 100; higher scores indicate worse symptoms.
Time frame: Baseline and Day 1 of each 21-day cycle from Cycle 2 until the end-of-treatment visit, up to approximately 26 months
Change from baseline in the percentage of myeloid-derived suppressor cells (MDSCs) in peripheral blood, measured by flow cytometry
Percentage of CD11b+CD33+HLA-DR- myeloid-derived suppressor cells among peripheral blood mononuclear cells, measured by flow cytometry.
Time frame: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
Change from baseline in the percentage of CXCR5+ cells among peripheral blood CD8+ T cells, measured by flow cytometry
Percentage of CXCR5-expressing cells among CD3+CD8+ T cells in peripheral blood mononuclear cells, measured by flow cytometry.
Time frame: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
Change from baseline in the percentage of CXCR5+ cells among peripheral blood CD4+ T cells, measured by flow cytometry
Percentage of CXCR5-expressing cells among CD3+CD4+ T cells in peripheral blood mononuclear cells, measured by flow cytometry.
Time frame: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
Change from baseline in the proportions of peripheral blood immune cell subsets, measured by single-cell RNA sequencing
Percentage of each immune cell subset (including CD8+ and CD4+ T-cell states, natural killer cells, monocytes and myeloid-derived suppressor cells) among all peripheral blood mononuclear cells, identified by single-cell RNA sequencing.
Time frame: Baseline (1-3 days before the first BMS-TACE); 24 hours, 1 month and 3 months after the first BMS-TACE; and at disease progression or end of treatment, up to approximately 26 months.
Change in the proportions of immune and stromal cell subsets in tumor tissue, measured by single-cell RNA sequencing
Percentage of each cell subset (including T-cell, myeloid, endothelial and fibroblast subsets) among all cells sequenced from tumor tissue, compared between pretreatment and post-treatment samples. Post-treatment samples are obtained from participants with objective response and from those with stable or progressive disease.
Time frame: Baseline (pretreatment tumor biopsy) and at post-treatment tumor sampling (conversion surgery, or biopsy at documented objective response or disease progression), assessed up to approximately 26 months
Change in the spatial cell-type composition of tumor tissue, measured by spatial transcriptomics
Percentage of spatial transcriptomic capture spots assigned to each cell type by cell-type deconvolution, in the tumor core and at the invasive margin, compared between pretreatment and post-treatment tumor samples.
Time frame: Baseline (pretreatment tumor biopsy) and at post-treatment tumor sampling (conversion surgery, or biopsy at documented objective response or disease progression), assessed up to approximately 26 months
Plan to share: Yes — De-identified individual participant data underlying the published results, together with the data dictionary, will be shared with investigators whose proposed use of the data has been approved by the study steering group.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 6 months and ending 36 months after publication of the primary results.
Access criteria: Requests should be submitted in writing to the principal investigator. Proposals will be reviewed by the study steering group, and approved requesters must sign a data use agreement before data are released.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2028, 25 months after the start.
Of 351 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 25 months is below that.
Counting every sponsor, half of 431 studies reached it within 43 months; a quarter within 30 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.